Dr. Alain Vertès brings extensive experience in the pharmaceutical and industrial biotechnology sectors across Europe, North America, and Asia. He is currently the Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland. In this role, he advises clients on strategy, business development, in/out-licensing, entrepreneurship, and investment, with a focus on cell- and gene-based therapies, oncology, inflammation, neurodegenerative diseases, and rare diseases. Dr. Vertès is also active in alliance management and external innovation for Mesoblast. His career includes significant positions at major pharmaceutical companies such as Lilly and Pfizer, where he held roles of increasing responsibility.

​

At Roche, Dr. Vertès led the global cell therapeutics strategy and implementation team through an external innovation partnering function from 2007 to 2010. His diverse background also includes work in petrochemicals and sustainable chemistry at Mitsubishi Chemical Corporation, public research at the Institut Pasteur and RITE/Kyoto, and contract research at Battelle Memorial Institute and PPD/BioDuro. Additionally, he has consulted for the Australian Strategic Policy Institute. With a strong focus on innovation commercialization, Dr. Vertès has been instrumental in the evaluation, selection, deal-making, implementation, and alliance management of numerous novel products and emerging technologies. He is also a lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.